Использование аспирина с целью снижения риска развития первого осложнения сосудистого заболевания у больных со средним уровнем риска развития сердечно-сосудистых заболеваний: результаты рандомизированного двойного слепого плацебо-контролируемого исследования ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events)

Авторы:
  • Редакция
Журнал: Доказательная кардиология (электронная версия, архив до 2019). 2018;11(3): 4-9
Просмотрено: 652 Скачано: 215

Источник: Gaziano J.M., Brotons C., Coppolecchia R., et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 2018; published online Aug 26. https://doi.org/10.1016/S0140- 6736(18)31924-X.

КАК ЦИТИРОВАТЬ:

Редакция Использование аспирина с целью снижения риска развития первого осложнения сосудистого заболевания у больных со средним уровнем риска развития сердечно-сосудистых заболеваний: результаты рандомизированного двойного слепого плацебо-контролируемого исследования ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events). Доказательная кардиология (электронная версия, архив до 2019). 2018;11(3):4-9.

Список литературы:

  1. Guirguis-Blake J.M., Evans C.V., Senger C.A., et al. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2016;164:804—813.
  2. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849—1860.
  3. Smith S.C. Jr, Benjamin E.J., Bonow R.O., et al. World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011;124:2458—2473.
  4. Bibbins-Domingo K. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2016;164:836—845.
  5. Piepoli M.F., Hoes A.W., Agewall S., et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2315—2381.
  6. Peto R., Gray R., Collins R., et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988; 296: 313—316.
  7. Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. Steering Committee of the Physicians’ Health Study Research Group. N Engl J Med 1989;321:129—135.
  8. The Medical Research Council’s General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998;351:233—241.
  9. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755—1762.
  10. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001;357:89—95.
  11. Ridker P.M., Cook N.R., Lee I.M, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293—1304.
  12. Ogawa H., Nakayama M., Morimoto T., et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300:2134—2141.
  13. Belch J., MacCuish A., Campbell I., et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a1840.
  14. Fowkes F.G., Price J.F., Stewart M.C., et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010;303:841—848.
  15. Ikeda Y., Shimada K., Teramoto T., et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 2014;312:2510—2520.
  16. US Food and Drug Administration. Citizen Petition Denial Response From FDA to Bayer Healthcare LLC. Docket ID: FDA- 1977-N0018. 2014. www.regulations.gov/#!documentDetail;D=FDA- 1977-N-0018-0101 (accessed March 3, 2016).
  17. Van’t Hof J.R., Duval S., Walts A., et al. Contemporary primary prevention aspirin use by cardiovascular disease risk: impact of US Preventive Services Task Force recommendations, 2007—2015: a serial, cross-sectional study. J Am Heart Assoc 20173;6:e006328.
  18. Whitlock E.P., Burda B.U., Williams S.B., et al. Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the US Preventive Services Task Force. Ann Intern Med 2016;164:826.
  19. Capodanno D., Angiolillo D.J. Aspirin for primary prevention of cardiovascular disease. Lancet 2018;392:988—990. https://doi.org/10.1016/S0140-6736(18)31990-1.
  20. Capodanno D., Patel A., Dharmashankar K., et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv 2011;4:180—187.
  21. Rothwell P.M., Cook N.R., Gaziano J.M., et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet 2018;392:387—399.
  22. Patrignani P., Patrono C. Aspirin and cancer. J Am Coll Cardiol 2016;68:967—976.